No Data
With Hong Kong Stock Connect funds accelerating the Buy, is CUTIA-B (02487)迎来 the last wave of excitement before the "out通"?
Just after the stock price hit the bottom, the Volume and Turnover Ratio of Kedi suddenly increased recently. Within a week, the stock price rose over 20%, showing an upward breakout trend, and there seems to be capital taking the last Buy opportunity before Kedi's public offering.
Hong Kong stocks movement | CUTIA-B (02487) rose over 7%, with a maximum increase of nearly 45% this month. Institutions state that the short-term growth in hair and cosmetics drives revenue growth.
CUTIA-B (02487) rose over 7%, with a maximum increase of nearly 45% within the month. As of the time of writing, it has risen by 7.86%, priced at 5.49 Hong Kong dollars, with a trading volume of 0.16 billion Hong Kong dollars.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Hong Kong stock movement | CUTIA-B (02487) rebounds nearly 30%, Institutions say that three major products under its wing are expected to be approved for launch successively.
CUTIA-B (02487) previously experienced a continuous decline in its stock price, but today it rebounded nearly 30% during trading. As of the time of writing, it has risen 22.03%, priced at 4.93 Hong Kong dollars, with a turnover of 0.196 billion Hong Kong dollars, and the total market value is still less than 1.6 billion Hong Kong dollars.
Cutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical Trial
Kedy-B (02487.HK): CU-20401 (recombinant mutated collagenase) achieved the main endpoint in phase II clinical trials for submental fat accumulation treatment.
On November 29, Gelonhui announced that the group's potential class 1 new drug CU-20401 (recombinant mutated collagenase) conducted a Phase II clinical trial for the treatment of submental fat accumulation in China has obtained top-line data. The data shows that the clinical trial has achieved the primary research endpoint, with results that are statistically significant and clinically meaningful. This clinical trial is a multicenter, randomized, double-blind, and placebo-controlled trial designed to evaluate the effectiveness and safety of CU-20401 in patients with moderate to severe submental fat accumulation, with a total of 108 subjects enrolled. The analysis results show.
